Last reviewed · How we verify
two-way education
At a glance
| Generic name | two-way education |
|---|---|
| Also known as | direct education |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial-based Economic Evaluation of a Mobile Health Intervention for Individuals With Chronic Non-specific Low Back Pain (NA)
- SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment (NA)
- Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth (NA)
- Developing a Community Support Program to Help People Quit Smoking. (NA)
- Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference (NA)
- Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel) (NA)
- Pilot Testing a Behavioral Intervention to Incorporate Advances in HIV Prevention for Black Young MSM in Alabama (NA)
- Scool of Pain (SchooP): A Way to Create Value in Healthcare? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- two-way education CI brief — competitive landscape report
- two-way education updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI